FY2022 Fact Sheet

Jeisys

Disclaimer

▶ it is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to uncertainties, changes in the organizational structure, redefinition of accounting policies, etc., and may cause the actual results to differ from those stated or implied in this material.

▶Audit of these results is still in progress. Figures in this disclosure are subject to change during the auditing process

I. P/L (K-IFRS)

Consolidated based on K-IFRS	2020					2021					2022				
(Unit : KRW million)	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative
Sales	**11,484**	**7,867**	**14,276**	**14,202**	**47,829**	**17,258**	**19,239**	**20,404**	**24,395**	**81,296**	**25,334**	**30,770**	**28,642**	**31,803**	**116,550**
Cost of Goods sold	3,569	2,831	3,149	4,541	14,090	4,712	5,913	6,026	7,998	24,649	7,638	10,056	9,160	10,121	36,975
Ratio(%)	31%	36%	22%	32%	29%	27%	31%	30%	33%	30%	30%	33%	32%	32%	32%
Gross profit	7,915	5,036	11,127	9,661	33,739	12,546	13,326	14,378	16,397	56,647	17,696	20,715	19,482	21,682	79,575
Ratio(%)	69%	64%	78%	68%	71%	73%	69%	70%	67%	70%	70%	67%	68%	68%	68%
SG&A	4,966	5,950	4,357	7,435	22,709	7,613	7,460	8,184	9,784	33,042	9,147	11,753	11,766	12,596	45,262
Operating profit	**2,949**	**-914**	**6,770**	**2,226**	**11,030**	**4,933**	**5,865**	**6,194**	**6,613**	**23,604**	**8,549**	**8,962**	**7,716**	**9,087**	**34,313**
Ratio(%)	26%	-12%	47%	16%	23%	29%	30%	30%	27%	29%	34%	29%	27%	29%	29%
Net profit before income tax	2,988	-2,767	6,525	1,468	8,215	-5,657	5,747	6,391	6,613	13,093	8,399	9,366	9,111	7,288	34,164
Net profit	**2,434**	**-2,622**	**6,250**	**1,481**	**7,543**	**-6,303**	**5,634**	**6,135**	**8,026**	**13,493**	**6,512**	**7,360**	**7,182**	**6,149**	**27,203**
Ratio(%)	21%	-33%	44%	10%	16%	-37%	29%	30%	33%	17%	26%	24%	25%	19%	23%
EBITDA	**3,404**	**-236**	**7,312**	**2,880**	**13,254**	**5,507**	**6,413**	**6,859**	**7,245**	**26,024**	**9,257**	**9,704**	**8,333**	**10,101**	**37,396**
Ratio(%)	30%	-3%	51%	20%	28%	32%	33%	34%	30%	32%	37%	32%	29%	32%	32%

Note1) 2021 1Q _ Other losses (Merger cost KRW 10,569million)

II. Sales by product portfolio (K-IFRS)

Consolidated based on K-IFRS	2020					2021					2022				
(Unit : KRW million)	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative
HIFU	2,036	2,918	2,207	3,036	10,198	3,304	3,466	3,601	2,645	13,015	3,628	3,062	5,945	4,645	17,280
RF	2,584	464	1,375	2,605	7,028	3,974	2,994	3,837	5,881	16,686	7,058	9,355	5,923	9,065	31,402
IPL	861	604	599	1,106	3,170	514	661	946	2,378	4,499	1,234	2,010	1,340	1,359	5,943
LASER	1,336	381	591	416	2,724	1,591	2,007	2,295	1,797	7,690	2,503	2,596	3,418	2,392	10,908
Consumables	4,011	2,738	8,602	6,557	21,907	7,260	9,413	9,573	11,069	37,315	10,237	13,120	10,740	11,424	45,521
Others	655	762	902	482	2,801	615	699	153	625	2,091	674	628	1,277	2,918	5,496
Total	**11,484**	**7,867**	**14,276**	**14,202**	**47,829**	**17,258**	**19,239**	**20,404**	**24,395**	**81,296**	**25,334**	**30,770**	**28,642**	**31,803**	**116,550**

III. Sales by Regional (K-IFRS)

Consolidated based on K-IFRS	2020					2021					2022				
(Unit : KRW million)	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative
Domestic	2,208	1,792	2,644	2,567	9,211	2,459	2,848	3,093	3,743	12,144	3,433	3,894	4,882	4,737	16,946
Overseas	9,276	6,075	11,632	11,635	38,617	14,798	16,391	17,311	20,652	69,152	21,901	26,876	23,761	27,066	99,604
Total	**11,484**	**7,867**	**14,276**	**14,202**	**47,829**	**17,258**	**19,239**	**20,404**	**24,395**	**81,296**	**25,334**	**30,770**	**28,642**	**31,803**	**116,550**

IV. Major Device Sales

Total company	2020					2021					2022				
(Unit : EA)	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative
LinearFirm / LinearZ	**120**	**175**	**126**	**146**	**567**	**164**	**196**	**212**	**171**	**743**	**238**	**186**	**312**	**236**	**972**
Cumulative Sales	988	1,163	1,289	1,435	-	1,599	1,795	2,007	2,178	-	2,416	2,602	2,914	3,150	-
POTENZA	**100**	**13**	**70**	**91**	**274**	**175**	**99**	**108**	**192**	**574**	**300**	**410**	**197**	**325**	**1,232**
Cumulative Sales	287	300	370	461	-	636	735	843	1,035	-	1,335	1,745	1,942	2,267	-

V. B/S (K-IFRS)

Consolidated based on K-IFRS	2020					2021					2022				
(Unit : KRW million)	1Q	2Q	3Q	4Q	12/31	1Q	2Q	3Q	4Q	12/31	1Q	2Q	3Q	4Q	12/31
Current assets	21,816	20,097	26,984	28,264	28,264	41,060	39,180	46,012	54,173	54,173	61,487	67,776	69,877	74,483	74,483
Cash and cash equivalents	7,759	9,533	17,047	17,591	17,591	19,582	23,263	28,668	34,291	34,291	36,394	32,274	33,627	39,583	39,583
Short-term trade Receivable	5,145	3,041	2,562	3,338	3,338	5,945	5,144	5,183	6,872	6,872	8,198	11,000	9,433	10,343	10,343
Inventories	6,993	5,888	5,653	5,766	5,766	6,190	8,171	9,679	10,578	10,578	13,234	18,329	20,423	20,380	20,380
Non-current assets	8,797	10,368	10,153	10,903	10,903	10,829	11,316	12,468	19,886	19,886	23,692	27,686	35,460	43,568	43,568
Total assets	**30,613**	**30,465**	**37,136**	**39,167**	**39,167**	**51,889**	**50,496**	**58,481**	**74,059**	**74,059**	**85,178**	**95,462**	**105,337**	**118,052**	**118,052**
Current liabilities	23,901	10,429	10,668	12,918	12,918	12,957	14,799	14,548	24,027	24,027	24,757	29,097	23,923	26,331	26,331
Non-current liabilities	13,217	16,669	11,157	9,290	9,290	9,936	8,678	8,569	2,379	2,379	4,040	3,995	10,485	11,579	11,579
Total liabilities	**37,118**	**27,098**	**21,825**	**22,208**	**22,208**	**22,893**	**23,477**	**23,117**	**26,405**	**26,405**	**28,797**	**33,092**	**34,409**	**37,910**	**37,910**
Issued capital	2,048	2,767	3,043	3,043	3,043	7,063	7,063	7,130	7,130	7,130	7,130	7,130	7,130	7,130	7,130
Total equity	**-6,505**	**3,367**	**15,312**	**16,959**	**16,959**	**28,996**	**27,020**	**35,364**	**47,654**	**47,654**	**56,381**	**62,370**	**70,928**	**80,141**	**80,141**

Jeisys Medical Inc.

Hang-In Lee (IR Team leader) / Mail : hilee@jeisys.com